deldeprevir (ACH-2684) / AstraZeneca - LARVOL DELTA

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro. (PubMed, Antimicrob Agents Chemother) - "Linear PI boceprevir, telaprevir and narlaprevir had 50% effective concentrations (EC50) of ∼40 μM. Among macrocyclic PI, simeprevir had the highest (EC50 15 μM) and glecaprevir the lowest (EC50 >178 μM) potency, with paritaprevir, grazoprevir, voxilaprevir, vaniprevir, danoprevir and deldeprevir in between. Acyclic PI asunaprevir and faldaprevir had EC50 of 72 and 23 μM, respectively...Viral suppression was achieved with 3- to 8-fold EC50 boceprevir or 1-fold EC50 simeprevir or grazoprevir, but not boceprevir, in combination with 0.4- to 0.8-fold EC50 remdesivir; these concentrations did not lead to viral suppression in single treatments. This study could inform development and application of protease inhibitors for optimized antiviral treatments of COVID-19."

Journal • Preclinical • Gastrointestinal Cancer • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Inflammation • Liver Cancer • Lung Cancer • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor

Achillion reports 2013 fourth quarter and year-end financial results (Achillion Press Release) - Anticipated completion of P1 drug-drug interaction study evaluating ACH-3102 and ACH-2684 in Q2 2014; Anticipated initiation of P2 trial evaluating ACH-3102 with ACH-2684 in Q2 2014; Anticipated initiation of P1 trial with ACH-3422 outside US in Q2 2014; Anticipated initiation of clinical trial with ACH-3422 in combination with other agents by the end of 2014; Anticipated initiation of P2 trial in Q2 2014 with ACH-3102 and sofosbuvir for durations of 8 weeks and less for the treatment of genotype 1 HCV; Anticipated submission and response from the FDA regarding the clinical hold on sovaprevir in H1 2014. "For the year ended December 31, 2013, the Company reported a net loss of $59.0 million, compared to a net loss of $47.1 million in 2012."

Anticipated FDA event • Anticipated new P1 trial • Anticipated new P2 trial • Anticipated new trial • Anticipated trial completion date • Commercial • Hepatitis C Virus

Combinatory effect of direct anti-HCV agents on antiviral efficacy and viral resistance in genotype-1a and -1b replicons as well as replicons carrying NS3 protease or NS5A protein from patient isolates (AASLD 2011) - Presentation time: Nov 05 2:00 PM - 7:30 PM; A standard 3 day combination study with ACH-2684 and novel NS5A inhibitor (compound A) in the absence of ribavirin yielded an additive to synergistic antiviral effect; Combination of these two agents significantly blocked the emergence of resistant variants

Preclinical-other • Hepatitis C Virus

Achillion reports HCV pipeline progress and outlines 2014 HCV milestones (Achillion Press Release) - Anticipated initiation of P1 first-in-human trial ex-US in Q2 2014 and P1 proof-of-concept trial in mid-2014 for ACH-3422 in HCV pts; Anticipated initial results from HCV-infected patients in Q3 2014 for ACH-3422; Anticipated initiation of pilot P2 study early in Q2 2014 for ACH-3102 + sofosbuvir in treatment-naive HCV pts; Anticipated initiation of P2 combination study for ACH-3422 by year-end 2014; Anticipated initiation of P2 trial early 2015 for ACH-3422 + ACH-3102 ± NS3/4A protease inhibitor in treatment-naive HCV pts; Anticipated initiation of P1 drug-drug interaction study in Q1 2014 and anticipated initiation of proof-of-concept study in mid-2014 for ACH-3102 + ACH-2684; Anticipated complete response package on the previously disclosed sovaprevir clinical hold and anticipated response from the FDA by the end of H1 2014.

Anticipated FDA event • Anticipated new P1 trial • Anticipated new P2 trial • Hepatitis C Virus

Achillion: Oppenheimer Healthcare Conference (Achillion) - Anticipated launch of ACH-3422 + ACH-3102 +/- ACH-PI triple combo for hep C infection in 2016/2017

Anticipated launch • Hepatitis C Virus

Achillion: Oppenheimer Healthcare Conference (Achillion) - "ACH-2684 proof of concept study"; "Significant antiviral activity demonstrated in GT1 patients"; "3 day proof of concept study evaluated treatment-naive HCV GT1 patients, either with and without cirrhosis: Significant antiviral activity demonstrated in HCV GT1 patients: Equivalent activity despite presence of cirrhosis; ACH-2684 was well tolerated in the study with no SAEs or patient discontinuations reported during treatment"

Clinical data • Hepatitis C Virus